Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma (MCL).

A study presented at the 2020 AACR Virtual Meeting tested the activity of TG-1701 when combined with ublituximab and umbralisib in ibrutinib-resistant MCL. Interest in TG-1701 comes from the fact that there is a large interest regarding BTK inhibitors for B-cell malignancies, says Roué. This is due to the fact that most first- or second-generation molecules have nonspecific activity but could impact other signals within the tumor B-cells. This molecule draws a lot of interest within the MCL space as it is more specific to the BTK pathway, explains Roué.

Another point of interest is that when investigators compared the second-generation molecule with the first-in-class inhibitor, ibrutinib, they found that some activity was retained in cases of resistance to ibrutinib, concludes Roué.